Federal Court in Canada Upholds Pfizer's Norvasc Patent; Decision Prevents Launch of Generic Amlodipine Besylate Product by Pharmascience until 2010

NEW YORK--(BUSINESS WIRE)--Apr 17, 2008 - Pfizer Inc said today that the Canadian Federal Court has upheld a Pfizer patent covering amlodipine besylate, the active ingredient in Norvasc. The court issued an order prohibiting regulatory approval of Pharmascience's proposed product in Canada until Pfizer's amlodipine besylate patent - Canadian Patent No. 1,321,393 - expires in August 2010. Pharmascience may appeal the decision to the Federal Court of Appeal of Canada.

The company noted that legal challenges to this patent in Canada by other generic manufacturers are still pending.

Contact

Pfizer Inc
Chris Loder, 212-733-7897

Posted: April 2008


View comments

Hide
(web1)